Xencor Stock (NASDAQ:XNCR), Trade Ideas

Xencor

Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AAOI

ALEC

ALHC

AMCX

AMRX

AMZN

ATSG

BIGC

BKNG

COLL

CYTK

DKNG

DVAX

FUBO

GDYN

INVE

IRTC

KTOS

KURA

LOPE

NTRA

OLED

OSUR

PRDO

TEAM

TRUP

TWST

XNCR

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session.

Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday

Short Ideas

Pre-Market Outlook

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MLTX

PTGX

TGTX

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Top 5 Health Care Stocks That May Collapse In February

Biotech

Earnings

Large Cap

Health Care

Contracts

General

ABBV

ACIU

ALLR

AXLA

BPMC

CLLS

ESPR

HALO

INCY

KRYS

LXRX

NAUT

RGEN

RHHBY

RIGL

RYTM

SAGE

SRPT

VALN

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study

Xencor Inc

<p>In the preceding three months, 6 analysts have released ratings for Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.33, along with a high estimate of $50.00 and a low estimate of $24.00. Experiencing a 21.84% decline, the current average is now lower than the previous average price target of $45.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713290555_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Xencor among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaveri Pohlman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$38.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Mara Goldstein</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$59.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Xencor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Xencor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Xencor's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Xencor's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XNCR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Xencor analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Xencor</h2>
<p>Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.</p>
<h3>Breaking Down Xencor's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Xencor's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>106.8%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Xencor's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-42.74%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Xencor's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-2.86%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Xencor's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-2.21%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Xencor's debt-to-equity ratio is below the industry average. With a ratio of <b>0.12</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Analyst Scoreboard: 6 Ratings For Xencor

<p>BTIG  analyst Kaveri Pohlman   maintains Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Buy and lowers the price target from $56 to $38.</p>


Price Target

BTIG Maintains Buy on Xencor, Lowers Price Target to $38

Management

Xencor Appoints Bart Cornelissen As Chief Financial Officer

<p>Piper Sandler  analyst Edward Tenthoff   downgrades Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) from Overweight to Neutral and lowers the price target from $37 to $24.</p>


Downgrades

Piper Sandler Downgrades Xencor to Neutral, Lowers Price Target to $24

WIIM

Xencor shares are trading lower after the company reported worse-than-expected Q4 financial results. Also, BMO Capital and Wedbush lowered their respective price targets on the stock.

<p>Ratings for Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Xencor and provided 12-month price targets. The average target is $37.5, accompanied by a high estimate of $50.00 and a low estimate of $32.00. Highlighting a 15.41% decrease, the current average has fallen from the previous average price target of $44.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709136069_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Xencor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Mara Goldstein</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$59.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Xencor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Xencor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Xencor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Xencor's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XNCR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Xencor analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Xencor: A Closer Look</h2>
<p>Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.</p>
<h3>Xencor's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Xencor's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately <strong>116.73%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Xencor's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-41.02%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Xencor's ROE excels beyond industry benchmarks, reaching <strong>-3.6%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Xencor's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-3.12%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Xencor's debt-to-equity ratio is below the industry average. With a ratio of <b>0.09</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Unveiling 4 Analyst Insights On Xencor

<p>RBC Capital  analyst Gregory Renza   reiterates Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Outperform and maintains $32 price target.</p>


Reiteration

RBC Capital Reiterates Outperform on Xencor, Maintains $32 Price Target

<p>BMO Capital  analyst Etzer Darout   maintains Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Outperform and lowers the price target from $38 to $34.</p>


BMO Capital Maintains Outperform on Xencor, Lowers Price Target to $34

<p>Wedbush  analyst David Nierengarten   maintains Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Outperform and lowers the price target from $36 to $34.</p>


Wedbush Maintains Outperform on Xencor, Lowers Price Target to $34

<p><strong>Xencor</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:01 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Xencor missed estimated earnings by -244.0%, reporting an EPS of $-0.31 versus an estimate of $-0.09.</p>
<p>Revenue was up $23.08 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.33 which was followed by a 7.000000000000001% drop in the share price the next day.</p>
<p>Here's a look at Xencor's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.73</td>
<td>-0.91</td>
<td>-0.66</td>
<td>-0.79</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.40</td>
<td>-0.37</td>
<td>-1.02</td>
<td>-0.20</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>29.32M</td>
<td>20.73M</td>
<td>27.97M</td>
<td>20.06M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>59.16M</td>
<td>45.52M</td>
<td>18.96M</td>
<td>21.61M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Xencor <a href="https://www.benzinga.com/quote/XNCR/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: Xencor Q4 Earnings

<p>Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.09) by 244.44 percent.  The company reported quarterly sales of $44.69 million which missed the analyst consensus estimate of $73.84 million by 39.48 percent.  This is a 106.80 percent increase over sales of $21.61 million the same period last year.</p>


Earnings Misses

Xencor Q4 2023 GAAP EPS $(0.31) Misses $(0.09) Estimate, Sales $44.69M Miss $73.84M Estimate

<p><strong>Xencor</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-02-27. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Xencor will report an <strong>earnings per share</strong> (EPS) of $-0.09. </p>
<p>Xencor bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.33, which was followed by a 7.01% drop in the share price the next day.</p>
<p>Here's a look at Xencor's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.73</td>
<td>-0.91</td>
<td>-0.66</td>
<td>-0.79</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.40</td>
<td>-0.37</td>
<td>-1.02</td>
<td>-0.20</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>4.0%</td>
<td>-2.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1708963294_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Xencor were trading at $24.47 as of February 23. Over the last 52-week period, shares are down 21.16%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/XNCR/earnings"><strong>To track all earnings releases for Xencor visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview: Xencor

<p>Across the recent three months, 4 analysts have shared their insights on Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $38.0, a high estimate of $50.00, and a low estimate of $32.00. Experiencing a 11.63% decline, the current average is now lower than the previous average price target of $43.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1705939246_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Xencor among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mara Goldstein</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Xencor. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Xencor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Xencor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Xencor's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XNCR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Xencor analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Xencor</h2>
<p>Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.</p>
<h3>Financial Milestones: Xencor's Journey</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Xencor's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>116.73%</strong> as of 30 September, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Xencor's net margin excels beyond industry benchmarks, reaching <strong>-41.02%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Xencor's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-3.6%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-3.12%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Xencor's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.09</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Navigating 4 Analyst Ratings For Xencor

<p>Mizuho  analyst Mara Goldstein   maintains Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Buy and lowers the price target from $59 to $50.</p>


Mizuho Maintains Buy on Xencor, Lowers Price Target to $50

<p>Guggenheim  analyst Michael Schmidt   maintains Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Buy and lowers the price target from $40 to $34.</p>


Guggenheim Maintains Buy on Xencor, Lowers Price Target to $34

<p>RBC Capital  analyst Gregory Renza   maintains Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Outperform and lowers the price target from $36 to $32.</p>


RBC Capital Maintains Outperform on Xencor, Lowers Price Target to $32

<p>Wedbush  analyst David Nierengarten   maintains Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) with a Outperform and lowers the price target from $37 to $36.</p>


Wedbush Maintains Outperform on Xencor, Lowers Price Target to $36

<p>Xencor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale of portions of financial interests from Alexion Pharmaceuticals, Inc., on sales of Ultomiris&#xAE; (ravulizumab-cwvz) and from MorphoSys AG on sales of Monjuvi&#xAE; (U.S.)/Minjuvi&#xAE; (ex-U.S.) (tafasitamab-cxix) to OMERS, one of Canada's largest defined benefit pension plans.</p>
<p>Under the agreements, Xencor has received a $215 million payment from OMERS. OMERS has acquired royalties due to Xencor on global Ultomiris sales from July 1, 2023 onward, with annual caps beginning in 2026, and the majority of a milestone payment earned this year. Xencor will also be eligible for a new Ultomiris sales-based milestone payment from OMERS. OMERS has also acquired royalties on global Monjuvi sales from July 1, 2023 until OMERS has received 1.3 times the value of the Monjuvi purchase price.</p>
<p>"Xencor's modular XmAb&#xAE; Fc domains and technologies are the foundation that enables our diversified approach to building value. Our platforms have been fundamental to the creation of three XmAb-based medicines marketed by partners, generating royalty income that drives further innovations in protein engineering and supports the advancement of our internal pipeline," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "A strengthened financial position offers us additional flexibility to execute on our internal clinical development programs with the greatest potential for success, and importantly, we are retaining potential economic upside from the sales performance of Ultomiris and Monjuvi/Minjuvi."</p>
<p><i>Ultomiris&#xAE; is a registered trademark of Alexion Pharmaceuticals, Inc. Monjuvi&#xAE; and Minjuvi&#xAE; are registered trademarks of MorphoSys AG.</i></p>


Asset Sales

Xencor Sells Portion Of Royalties And Milestones From Ultomiris And Monjuvi To OMERS Life Sciences For $215M

<p><strong>Xencor</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) reported its Q3 earnings results on Tuesday, November 7, 2023 at 04:01 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Xencor beat estimated earnings by 45.21%, reporting an EPS of $-0.4 versus an estimate of $-0.73.</p>
<p>Revenue was up $31.86 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.54 which was followed by a 3.55% increase in the share price the next day.</p>
<p>Here's a look at Xencor's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
<th><strong>Q3 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.91</td>
<td>-0.66</td>
<td>-0.79</td>
<td>-0.68</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.37</td>
<td>-1.02</td>
<td>-0.20</td>
<td>-0.55</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>20.73M</td>
<td>27.97M</td>
<td>20.06M</td>
<td>20.96M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>45.52M</td>
<td>18.96M</td>
<td>21.61M</td>
<td>27.30M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Xencor <a href="https://www.benzinga.com/quote/XNCR/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: Xencor Q3 Earnings

<p>Xencor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.73) by 45.21 percent. This is a 27.27 percent increase over losses of $(0.55) per share from the same period last year.  The company reported quarterly sales of $59.16 million which beat the analyst consensus estimate of $29.32 million by 101.79 percent.  This is a 116.73 percent increase over sales of $27.30 million the same period last year.</p>


Xencor Q3 2023 Gaap EPS $(0.40) Beats $(0.73) Estimate, Sales $59.16M Beat $29.32M Estimate

Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript

Barclays analyst Peter Lawson reiterated a Sell rating on Xencor (XNCR – Research Report) yesterday and set a price target of $22.00. The company's...

Barclays Sticks to Their Sell Rating for Xencor (XNCR)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xencor (XNCR – Research Report) and Vaxcyte (PCVX – ...

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Vaxcyte (PCVX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alcon (ALC – Research Report), Xencor (XNCR – Resear...

Analysts Are Bullish on Top Healthcare Stocks: Alcon (ALC), Xencor (XNCR)

Xencor Inc (XNCR) missed earnings projections on 2/27/2024 for Q4 2023.Xencor Inc's earnings came in at an EPS loss of $0.31 per share, 244% lower than estimates for an EPS loss of $0.09 per share. The firm's loss per share expanded by 55% since reporting a loss of $0.2 per share a year ago. Consensus analyst estimates wer

Xencor Inc Down 16.41% To $22.17 After Earnings Miss

Xencor slips as Piper cuts citing patient death in cancer study

Xencor Inc. (XNCR) has disclosed a new risk, in the Share Price & Shareholder Rights category. Xencor Inc. faces heightened scrutiny as the emphasi...

Bad News for Xencor Inc. Stock: This New Risk Has Been Added

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on XNCR stock, giving a Buy rating on February 28. Jonathan Chang has g...

Xencor's Strategic Focus and Pipeline Progress Affirm Buy Rating

Xencor names Bart Cornelissen to CFO

Xencor Inc (XNCR) has provided an update. John Kuch is set to retire from his CFO position at Xencor, Inc. on March 31, 2024, and Bart Cornelissen ...